From Diagnostic‐Therapeutic Pathways to Real‐World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR‐Positive Non‐Small Cell Lung Cancer (MOST Study)

• Published in: The oncologist (Dayton, Ohio) Ohio), 2019-06, Vol.24 (6), p.e318-e326
• Main Authors: Pasello, Giulia, Vicario, Giovanni, Zustovich, Fable, Oniga, Francesco, Gori, Stefania, Rosetti, Francesco, Bonetti, Andrea, Favaretto, Adolfo, Toso, Silvia, Redelotti, Roberta, Santo, Antonio, Bernardi, Daniele, Giovanis, Petros, Oliani, Cristina, Calvetti, Lorenzo, Gatti, Carlo, Palazzolo, Giovanni, Baretta, Zora, Bortolami, Alberto, Bonanno, Laura, Basso, Marco, Menis, Jessica, Corte, Donatella Da, Frega, Stefano, Guarneri, Valentina, Conte, PierFranco
• Format: Article
• Language: English
• Subjects: Epidermal growth factor receptor; Health Outcomes and Economics of Cancer Care; Non‐small cell lung cancer; Real world; Tyrosine kinase inhibitor
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.2018-0712

Introduction Gefitinib, erlotinib, and afatinib represent the approved first‐line options for epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC). Because pivotal trials frequently lack external validity, real‐world data may help to depict the diagnostic‐therapeutic pathway and treatment outcome in clinical practice. Methods MOST is a multicenter observational study promoted by the Veneto Oncology Network, aiming at monitoring the diagnostic‐therapeutic pathway of patients with nonsquamous EGFR‐mutant NSCLC. We reported treatment outcome in terms of median time to treatment failure (mTTF) and assessed the impact of each agent on the expense of the regional health system, comparing it with a prediction based on the pivotal trials. Results An EGFR mutation test was performed in 447 enrolled patients, of whom 124 had EGFR mutation and who received gefitinib (n = 69, 55%), erlotinib (n = 33, 27%), or afatinib (n = 22, 18%) as first‐line treatment. Because erlotinib was administered within a clinical trial to 15 patients, final analysis was limited to 109 patients. mTTF was 15.3 months, regardless of the type of tyrosine kinase inhibitor (TKI) used. In the MOST study, the budget impact analysis showed a total expense of €3,238,602.17, whereas the cost estimation according to median progression‐free survival from pivotal phase III trials was €1,813,557.88. Conclusion Good regional adherence and compliance to the diagnostic‐therapeutic pathway defined for patients with nonsquamous NSCLC was shown. mTTF did not significantly differ among the three targeted TKIs. Our budget impact analysis suggests the potential application of real‐world data in the process of drug price negotiation. Implications for Practice The MOST study is a real‐world data collection reporting a multicenter adherence and compliance to diagnostic‐therapeutic pathways defined for patients with epidermal growth factor receptor‐mutant non‐small cell lung cancer. This represents an essential element of evidence‐based medicine, providing information on patients and situations that may be challenging to assess using only data from randomized controlled trials, e.g., turn‐around time of diagnostic tests, treatment compliance and persistence, guideline adherence, challenging‐to‐treat populations, drug safety, comparative effectiveness, and cost effectiveness. This study may be of interest to various stakeholders (patients, clinicians, and payers), providing a meaningful pi